Products
Ibentatug Biosimilar Monoclonal Antibody (CSP1) for Research
Cat No.: GMP-Bios-INN-1227
Anti-CSP1 therapeutic antibody (Pre-made Ibentatug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ibentatug (development code ZB-131) is a monoclonal antibody targeting CSP1. It is developed by ZielBio for cholangiocarcinoma, ovarian cancer, pancreatic cancer, and other solid tumors. It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1227-1mg | 1mg | 3090 |
| GMP-Bios-INN-1227-10mg | 10mg | |
| GMP-Bios-INN-1227-100mg | 100mg | |
| GMP-Bios-INN-1227-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ibentatug biosimilar, Whole mAb, Anti-CSP1 Antibody: Anti-Calcipressin 1/RCAN1/Calcipressin-1/Adapt78 therapeutic antibody |
| INN Name | Ibentatug |
| Target | CSP1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | ZielBio |
| Conditions Approved | na |
| Conditions Active | Cholangiocarcinoma;Ovarian cancer;Pancreatic cancer;Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
